

Form PTO-1595 (Rev. 07/05)
OMB No. 0651-0027 (exp. 6/30/2008)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)
Syn X Pharma Inc.

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: Nanogen Point of Care Inc.
Internal Address: _____

3. Nature of conveyance/Execution Date(s):
Execution Date(s) February 9, 2006
 Assignment Merger
 Security Agreement Change of Name
 Joint Research Agreement
 Government Interest Assignment
 Executive Order 9424, Confirmatory License
 Other _____

Street Address: 1 Marmac Drive

City: Toronto
State: Ontario
Country: Canada Zip: M9W 1E7
Additional name(s) & address(es) attached? Yes No

4. Application or patent number(s):
A. Patent Application No.(s)
09/993,289

Additional numbers attached? Yes No

This document is being filed together with a new application.
B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address to whom correspondence concerning document should be mailed:
Name: McHale & Slavin, P.A.
Internal Address: _____
Street Address: 2855 PGA Boulevard
City: Palm Beach Gardens
State: FL Zip: 33410
Phone Number: (561) 625-6575
Fax Number: (561) 625-6572
Email Address: palmbeach@m spatents.com

6. Total number of applications and patents Involved: 1
7. Total fee (37 CFR 1.21(h) & 3.41) \$40.00
 Authorized to be charged by credit card
 Authorized to be charged to deposit account
 Enclosed
 None required (government interest not affecting title)

8. Payment Information
a. Credit Card Last 4 Numbers _____
Expiration Date _____
b. Deposit Account Number 50-1803
Authorized User Name Nanogen

9. Signature: Ferris H. Lander
Signature
Name of Person Signing Ferris H. Lander

Date 6/28/2006
Total number of pages including cover sheet, attachments, and documents: **4**

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

CH \$40.00 501803 09993289

- 6. The amendment has been duly authorized as required by sections 168 and 170 (as applicable) of the *Business Corporations Act*.
La modification a été dûment autorisée conformément aux articles 168 et 170 (selon le cas) de la Loi sur les sociétés par actions.
- 7. The resolution authorizing the amendment was approved by the shareholders/directors (as applicable) of the corporation on
Les actionnaires ou les administrateurs (selon le cas) de la société ont approuvé la résolution autorisant la modification le

2006 February 9

(Year, Month, Day)
(année, mois, jour)

These articles are signed in duplicate.
Les présents statuts sont signés en double exemplaire.

SYNX PHARMA INC.

(Name of Corporation) (If the name is to be changed by these articles set out current name)
(Dénomination sociale de la société) (Si l'on demande un changement de nom, indiquer ci-dessus la dénomination sociale actuelle).

By/
Par:



(Signature)
(Signature)

Secretary

(Description of Office)
(Fonction)

SYNX PHARMA INC.
(the "Corporation")

RESOLUTION OF THE SHAREHOLDER

RECITALS:

- A. The Corporation proposes to change its name to **NANOGEN POINT OF CARE INC.**, and
- B. There are no reasonable grounds for believing that:
- (a) the Corporation is unable to pay its liabilities as they become due; or
 - (b) the realizable value of the Corporation's assets is less than the aggregate of its liabilities.

RESOLVED AS A SPECIAL RESOLUTION THAT:

1. The Articles of the Corporation be amended to change the name of the Corporation to **NANOGEN POINT OF CARE INC.**
2. Any director or officer of the Corporation is authorized and directed to take all such action and execute all such documents, including the execution and filing of Articles of Amendment, as such director or officer deems necessary or advisable in order to complete the matters provided for herein.
3. This resolution may be executed by means of facsimile signature and when so executed and delivered shall be an original.

The foregoing resolution is passed as evidenced by the signature of the shareholder of the Corporation entitled to vote pursuant to the provisions of the *Business Corporations Act* (Ontario).

DATED February 9, 2006.

NANOGEN, INC.

By: William L. Respass
William L. Respass
Senior Vice President, General Counsel
and Secretary